Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease.
作者信息
Brohée Sacha, Roze Emmanuel, Grabli David, Letrillart Hélène, Mantisi Lise, Foucard Cendrine, Hainque Elodie, Cormier Florence, Méneret Aurélie, Hauw Fabien
机构信息
Département de Neurologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital de La Pitié-Salpêtrière, Paris, France.
出版信息
Mov Disord Clin Pract. 2025 Jul;12(7):1028-1030. doi: 10.1002/mdc3.70060. Epub 2025 Mar 28.
Abstract
摘要
相似文献
1
Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease.左旋多巴/卡比多巴复方制剂对帕金森病患者认知及精神方面的不良影响
Mov Disord Clin Pract. 2025 Jul;12(7):1028-1030. doi: 10.1002/mdc3.70060. Epub 2025 Mar 28.
2
Licensed Subcutaneous Infusion Therapies in Advanced Parkinson's Disease: An Indirect Treatment Comparison and Cost-Minimisation Analysis.晚期帕金森病的皮下输注许可治疗：间接治疗比较与成本最小化分析
Neurol Ther. 2025 Jul 8. doi: 10.1007/s40120-025-00789-9.
3
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.晚期帕金森病患者连续皮下注射左多巴-卡比多巴的安全性和有效性：一项随机、双盲、阳性对照、3 期临床试验。
Lancet Neurol. 2022 Dec;21(12):1099-1109. doi: 10.1016/S1474-4422(22)00400-8.
4
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.帕金森病患者皮下持续输注左旋多巴/卡比多巴：一项为期12个月的单臂、开放标签3期研究的安全性和有效性结果
Neurol Ther. 2023 Dec;12(6):1937-1958. doi: 10.1007/s40120-023-00533-1. Epub 2023 Aug 26.
5
Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease.左旋多巴/卡比多巴复方制剂单药治疗帕金森病患者的疗效与安全性
Mov Disord Clin Pract. 2025 Jul 30. doi: 10.1002/mdc3.70245.
6
Foslevodopa/Foscarbidopa: A Review in Advanced Parkinson's Disease.左旋多巴/卡比多巴肠凝胶：晚期帕金森病的综述
CNS Drugs. 2025 Jun;39(6):621-632. doi: 10.1007/s40263-025-01179-3. Epub 2025 Apr 8.
7
Effects of the continuous subcutaneous infusion of foslevodopa-foscarbidopa on swallowing in patients with Parkinson's disease.持续皮下输注左旋多巴-卡比多巴对帕金森病患者吞咽功能的影响。
Clin Park Relat Disord. 2025 Jul 29;13:100378. doi: 10.1016/j.prdoa.2025.100378. eCollection 2025.
8
Clinical Impact of Switching from Subcutaneous Apomorphine to Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: A Real-World Observational Study (FOSAPO).晚期帕金森病患者从皮下注射阿扑吗啡转换为福沙左旋多巴/福沙卡比多巴的临床影响：一项真实世界观察性研究（FOSAPO）
Mov Disord Clin Pract. 2025 Jul 24. doi: 10.1002/mdc3.70254.
9
Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion.福司列弗多巴/福卡比多巴经皮下输注后具有良好的耐受性，并能维持稳定的左旋多巴和卡比多巴暴露量。
J Parkinsons Dis. 2021;11(4):1695-1702. doi: 10.3233/JPD-212813.
10
Continuous Subcutaneous Foslevodopa-Foscarbidopa in Parkinson's Disease: A Mini-Review of Current Scope and Future Outlook.帕金森病中持续皮下注射左多巴-卡比多巴：当前范围和未来展望的小型综述。
Mov Disord Clin Pract. 2024 Oct;11(10):1188-1194. doi: 10.1002/mdc3.14161. Epub 2024 Jul 11.
本文引用的文献
1
Levodopa Pharmacokinetics in Switching From Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson's Disease: A Case Report.帕金森病患者从左旋多巴/卡比多巴肠凝胶转换为持续皮下注射左旋多巴甲酯/卡比多巴甲酯的左旋多巴药代动力学：病例报告
J Mov Disord. 2025 Apr;18(2):179-181. doi: 10.14802/jmd.24247. Epub 2025 Jan 6.
2
Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance.持续皮下输注左旋多巴/卡比多巴用于治疗帕金森病的运动波动：起始和维持的注意事项
Clin Park Relat Disord. 2024 Feb 10;10:100239. doi: 10.1016/j.prdoa.2024.100239. eCollection 2024.
3
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.晚期帕金森病患者连续皮下注射左多巴-卡比多巴的安全性和有效性：一项随机、双盲、阳性对照、3 期临床试验。
Lancet Neurol. 2022 Dec;21(12):1099-1109. doi: 10.1016/S1474-4422(22)00400-8.
Zotero 插件